Biotech Dealmaker d’Epenoux to Chair Elkedonia’s Depression Drug Push

STRASBOURG, France – April 22, 2026 – In a strategic move signaling its ambition to tackle one of modern medicine's most persistent challenges, Franco-Belgian biotech firm Elkedonia has appointed veteran pharmaceutical executive Pierre d’Epenoux as its Independent Chairman. The appointment is poised to inject a wealth of deal-making and corporate strategy experience into the young company as it advances a novel class of non-hallucinogenic drugs for major depressive disorder (MDD).

Elkedonia, founded in 2025, is pioneering what it calls a “neuroplastogen” approach, aiming to restore brain connectivity without the psychoactive side effects that have limited the use of other rapid-acting antidepressants like ketamine. With d’Epenoux’s guidance, the company is preparing to navigate the complex journey from preclinical discovery to potential blockbuster therapeutic, a path he has successfully charted before.

A Proven Architect of Biotech Success

Pierre d’Epenoux is not just another executive addition; he is a recognized architect of high-value biotech exits. His most recent and notable success was as CEO of ImCheck Therapeutics, an immuno-oncology company he led from a Series A startup to a major acquisition. In 2025, global biopharma giant Ipsen acquired ImCheck in a landmark deal valued at up to €1 billion, a testament to the strategic value d’Epenoux built.

His 30-year career is marked by leadership roles focused on strategic transactions, licensing, and corporate development at major players like Sanofi, Baxter Healthcare, and Merck KGaA. This specific expertise is what Elkedonia’s leadership believes will be transformative for the company's next growth phase.

“Our team has built Elkedonia from the ground up with deep expertise in drug discovery, clinical development and corporate strategy, supported by a strong syndicate of European life sciences investors,” said Delphine Charvin, Chief Executive Officer and cofounder of Elkedonia. “Welcoming Pierre as Chairman brings a highly complementary skill set to the Board — his extensive experience in biotech-pharma partnerships, licensing and transactions will be invaluable as we strengthen our strategic positioning and build long-term value.”

D’Epenoux's role will be critical as Elkedonia matures its lead program and begins exploring the strategic partnerships and financing rounds necessary to fund costly clinical trials and, eventually, commercialization. His track record provides a blueprint for turning promising science into a tangible asset attractive to larger pharmaceutical partners or public markets.

Targeting Depression at its Source

Elkedonia’s scientific platform represents a significant departure from conventional antidepressants. For decades, the market has been dominated by drugs targeting neurotransmitters like serotonin. While helpful for many, these treatments can take weeks to work and are ineffective for a substantial portion of patients. More recently, the focus has shifted to neuroplasticity—the brain’s ability to form new neural connections—as a key mechanism for rapid antidepressant effects.

The company’s lead program targets the inhibition of an intracellular protein known as ELK1. Previously considered “undruggable,” ELK1 is a transcription factor that plays a crucial role in the brain's stress and reward pathways. Foundational research from Sorbonne University, which underpins Elkedonia's work, has shown that ELK1 levels are elevated in animal models of depression and that inhibiting its activation can prevent stress-induced depressive behaviors. This suggests ELK1 could be a direct lever to reverse the neural deficits underlying depression.

This approach places Elkedonia in the burgeoning field of neuroplastogens, compounds designed to promote synaptogenesis. Unlike first-generation psychoplastogens such as ketamine or psilocybin, Elkedonia’s molecules are engineered to be non-addictive and, crucially, non-hallucinogenic. This could eliminate the need for in-clinic supervision and monitoring required for psychedelic-based therapies, potentially offering a safer and more accessible treatment for millions.

“Elkedonia has the potential to drive breakthrough advancements in treating depression and its comorbidities and establish a leading position in the field of MDD in particular,” said Pierre d’Epenoux. “I look forward to joining Elkedonia’s experienced board and being a part of the next exciting phase of the company’s evolution.”

The Urgent Need and a Burgeoning Market

The scale of the mental health crisis Elkedonia aims to address is staggering. Major Depressive Disorder affects an estimated 332 million people globally, making it a leading cause of disability worldwide. In the United States and Europe, approximately 25 million people in each region suffer from the condition. The economic toll is equally immense, with lost productivity due to depression and anxiety costing the global economy over $1 trillion annually.

Even more concerning is the large population of patients who find no relief from existing options. Roughly one-third of individuals with MDD do not respond adequately to at least two different antidepressant treatments, a condition known as treatment-resistant depression (TRD). These patients face a higher risk of suicide and other comorbidities, highlighting an urgent and profound unmet medical need.

It is this high-need segment that Elkedonia is initially targeting. A successful, well-tolerated, and rapid-acting oral therapeutic for TRD would represent a paradigm shift in psychiatry and a multi-billion-dollar market opportunity, attracting significant interest from investors and pharmaceutical companies alike.

The Backing of Europe's Biotech Investors

Elkedonia’s promise has already captured the attention of a sophisticated syndicate of European life sciences investors. In 2025, the company, which was incubated by the venture studio Argobio, secured an oversubscribed €11.25 million seed financing round. The round was co-led by Kurma Partners and WE Life Sciences, with participation from Bpifrance, Angelini Ventures, and others.

This investor group brings more than just capital; it brings a track record of building successful biotech companies. Kurma Partners, for instance, was an early backer of d’Epenoux’s former company, ImCheck Therapeutics, and has seen other portfolio companies like Amolyt Pharma and Corlieve Therapeutics achieve successful acquisitions. The involvement of Bpifrance, the French public investment bank, underscores the national strategic interest in fostering breakthrough health-tech innovation.

This strong financial foundation, combined with d’Epenoux’s strategic leadership, places Elkedonia in a formidable position. As the company continues to advance its first-in-class ELK1 inhibitors, the industry will be watching closely to see if this combination of novel science and seasoned leadership can deliver a long-awaited new chapter in the treatment of depression.